Search

Displaying results 7681 - 7690 of 10000 in total
  1. Drug

    MK-0482

    go.drugbank.com/drugs/DB17453
    Investigational

    MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.

  2. Drug

    RO-7293583

    go.drugbank.com/drugs/DB17455
    Investigational

    RO-7293583 is a TYRP1-Targeting CD3 T-Cell Engager.

  3. Drug

    gp209-2M antigen

    go.drugbank.com/drugs/DB17462
    Investigational

    The gp209-2M antigen is derived from gp209, and has potential immunomodulatory and antineoplastic activities.

  4. Drug

    ETBX-011

    go.drugbank.com/drugs/DB17464
    Investigational

    ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).

  5. Drug

    LP-2307

    go.drugbank.com/drugs/DB17470
    Experimental

    LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.

  6. Drug

    Benmelstobart

    go.drugbank.com/drugs/DB17473
    Investigational

    APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).

    Synonyms: 贝莫苏拜单抗, gamma1 heavy chain humanized (1-446) [VH (Homo sapiens IGHV2-5*01 (78.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.7.10] (26-33.51-57.96-105)) (1-116)-Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14
  7. Drug

    Nanrilkefusp alfa

    go.drugbank.com/drugs/DB17480
    Investigational

    Nanrilkefusp alfa is a human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity binding sushi+ domain of IL-15 receptor alpha (IL-15Ra).

  8. Drug

    BI-765063

    go.drugbank.com/drugs/DB17482
    Investigational

    BI-765063 is a humanized IgG4 monoclonal antibody antagonist of signal regulatory protein α (SIRPα).

  9. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.

  10. Drug

    CGX-1321

    go.drugbank.com/drugs/DB17491
    Investigational

    CGX-1321 is a porcupine inhibitor that affects Wnt production and can block Wnt downstream signaling.[A257038]

    Categories: Heterocyclic Compounds, 2-Ring